Akebia Therapeutics (AKBA) Current Deferred Revenue (2016 - 2026)
Akebia Therapeutics (AKBA) reported Current Deferred Revenue of $6.17 million for Q2 2026, up 11.5% from $5.53 million a year earlier and up 37.2% from the prior quarter.
Powered by 
Analysis
Akebia Therapeutics (AKBA) Current Deferred Revenue (2016 - 2026) Analysis & Trends
At the end of FY2025, Akebia Therapeutics posted Current Deferred Revenue of $2.68 million.
- Current Deferred Revenue has a five-year compound annual growth rate of -29.3% (FY2020 to FY2025).
- By year, Current Deferred Revenue came in at $3.74 million in FY2022 (-82.1%) and $20.91 million in FY2021 (+37.4%).
- The Q2 2026 figure ranks as the highest quarterly Current Deferred Revenue since Q2 2024.
- Year over year, Current Deferred Revenue gained in three of the last four quarters, with growth averaging 66.3%.
- The high point for year-over-year Current Deferred Revenue in five years was Q1 2026 (growth of 262.3%); the low point was Q3 2022 (a decline of 91.9%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $4.5 million (Q1 2026), $2.68 million (Q4 2025) and $3.88 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn |
| 10 | Akebia Therapeutics | 149.86 Mn | -512.48 Mn | 30.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 4.96 Mn |
| Jun 30, 2026 | 6.17 Mn |
| Mar 31, 2026 | 4.50 Mn |
| Dec 31, 2025 | 2.68 Mn |
| Sep 30, 2025 | 3.88 Mn |
| Jun 30, 2025 | 5.53 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Jun 30, 2024 | 43.30 Mn |
| Mar 31, 2024 | 695,000.00 |
| Dec 31, 2022 | 3.74 Mn |
| Sep 30, 2022 | 1.27 Mn |
| Jun 30, 2022 | 5.05 Mn |
| Mar 31, 2022 | 10.44 Mn |
| Dec 31, 2021 | 20.91 Mn |
| Sep 30, 2021 | 15.69 Mn |
| Jun 30, 2021 | 11.87 Mn |
| Mar 31, 2021 | 18.25 Mn |
| Dec 31, 2020 | 15.21 Mn |
| Sep 30, 2020 | 18.03 Mn |
| Jun 30, 2020 | 23.53 Mn |
API Access
Akebia Therapeutics Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=AKBA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "AKBA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=AKBA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();